AVITA Medical (RCEL) investor relations material

Company overview and business model

• Operates as a therapeutic acute wound care company focused on optimizing wound healing and patient recovery for burns, traumatic injuries, and surgical repairs.

• Commercial portfolio includes RECELL (FDA-approved for thermal burns and skin defects), PermeaDerm, and Cohealyx, supporting comprehensive acute wound care.

• Expanded product offerings in 2024 and 2025 through exclusive distribution and manufacturing agreements for PermeaDerm and Cohealyx, with launches in the U.S. and potential expansion to the EU, Australia, and Japan.

Risk factors and disclosures

• Investment involves a high degree of risk, with detailed risk factors incorporated by reference from recent SEC filings, including the latest Annual Report and subsequent updates.

• Risks could materially affect business, operations, or financial condition, potentially leading to loss of investment.

Use of proceeds and capital allocation

• Net proceeds from securities sales are intended for general corporate purposes, including capital expenditures, working capital, and other purposes specified in future prospectus supplements.

• Pending specific application, proceeds may be invested in short-term marketable securities or used to reduce short-term debt.